

American Journal of Clinical Dermatology

**Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A
United States Cross-Sectional Survey**

Wenhui Wei,^{1*} Peter Anderson,² Abhijit Gadkari,³ Stuart Blackburn,² Rachel Moon,² James Piercy,² Shashank Shinde,¹
Jorge Gomez,³ Eric Ghorayeb¹

¹Sanofi, Bridgewater, NJ, USA; ²Adelphi Real World, Bollington, UK; ³Regeneron, Tarrytown, NY, USA

*Current address: Regeneron Pharmaceuticals, Inc. Tarrytown, NJ, USA

E-mail: wenhui.wei@regeneron.com

Electronic Supplementary Material:

Physician- and Patient-Reported Data on Current Disease Status

Electronic Supplementary Material Table 1. Physician-Reported Data: Current Disease Status at Clinic Visit

Variable ^a	Overall (N = 678)	Matched (n = 465)	Patient assessed higher (n = 76)	Physician assessed higher (n = 137)	p value
Total number of flares in the last 12 months					
Mean ± SD	2.2 ± 2.1	2.1 ± 2.0	2.8 ± 2.3	2.4 ± 2.4	0.0507
Missing	129	79	21	29	
Total number of baseline symptoms (day-to-day)					
Mean ± SD	5.4 ± 4.2	5.3 ± 4.2	5.5 ± 4.3	6.0 ± 4.4	0.2220
Missing	49	26	4	19	
Pruritus / itching, n (%)					
Not present day to day	164 (26.1)	121 (73.8)	18 (11.0)	25 (15.2)	0.3660
Present Day to day	465 (73.9)	318 (68.4)	54 (11.6)	93 (20.0)	
Missing	49	26	4	19	
Swelling, n (%)					
Not present day to day	365 (58.0)	255 (69.9)	45 (12.3)	65 (17.8)	0.6030
Present Day to day	264 (42.0)	184 (69.7)	27 (10.2)	53 (20.1)	
Missing (n)	49	26	4	19	
Cracking / raw areas, n (%)					
Not present day to day	299 (47.5)	208 (69.6)	36 (12.0)	55 (18.4)	0.8958
Present Day to day	330 (52.5)	231 (70.0)	36 (10.9)	63 (19.1)	
Missing	49	26	4	19	
Pain / soreness, n (%)					
Not present day to day	348 (55.3)	250 (71.8)	40 (11.5)	58 (16.7)	0.3185
Present Day to day	281 (44.7)	189 (67.3)	32 (11.4)	60 (21.4)	
Missing	49	26	4	19	
Blistering (non-oozing), n (%)					
Not present day to day	536 (85.2)	377 (70.3)	63 (11.8)	96 (17.9)	0.3974
Present Day to day	93 (14.8)	62 (66.7)	9 (9.7)	22 (23.7)	
Missing	49	26	4	19	

Variable^a	Overall (N = 678)	Matched (n = 465)	Patient assessed higher (n = 76)	Physician assessed higher (n = 137)	p value
Blistering (oozing), n (%)					
Not present day to day	558 (88.7)	392 (70.3)	62 (11.1)	104 (18.6)	0.7139
Present Day to day	71 (11.3)	47 (66.2)	10 (14.1)	14 (19.7)	
Missing	49	26	4	19	
Crusting, n (%)					
Not present day to day	415 (66.0)	291 (70.1)	52 (12.5)	72 (17.3)	0.2776
Present Day to day	214 (34.0)	148 (69.2)	20 (9.3)	46 (21.5)	
Missing	49	26	4	19	
Scaling, n (%)					
Not present day to day	299 (47.5)	213 (71.2)	36 (12.0)	50 (16.7)	0.4478
Present Day to day	330 (52.5)	226 (68.5)	36 (10.9)	68 (20.6)	
Missing	49	26	4	19	
Papules, n (%)					
Not present day to day	479 (76.2)	346 (72.2)	52 (10.9)	81 (16.9)	0.0500
Present Day to day	150 (23.8)	93 (62.0)	20 (13.3)	37 (24.7)	
Missing	49	26	4	19	
Skin colour change, n (%)					
Not present day to day	408 (64.9)	297 (72.8)	41 (10.0)	70 (17.2)	0.0792
Present Day to day	221 (35.1)	142 (64.3)	31 (14.0)	48 (21.7)	
Missing	49	26	4	19	
Infection in the skin					
Not present day to day	556 (88.4)	389 (70.0)	62 (11.2)	105 (18.9)	0.8083
Present Day to day	73 (11.6)	50 (68.5)	10 (13.7)	13 (17.8)	
Missing	49	26	4	19	
EASI, mean score ± SD	9.3 ± 8.3	9.2 ± 8.7	9.5 ± 7.6	9.5 ± 7.1	0.5308

Variable ^a	Overall (N = 678)	Matched (n = 465)	Patient assessed higher (n = 76)	Physician assessed higher (n = 137)	p value
EASI score group, n (%)					
0 – <5	243 (35.8)	171 (70.4)	26 (10.7)	46 (18.9)	0.7774
5 – <10	177 (26.1)	117 (66.1)	22 (12.4)	38 (21.5)	
10 – <15	122 (18.0)	89 (73.0)	13 (10.7)	20 (16.4)	
15 – <20	91 (13.4)	58 (63.7)	8 (8.8)	25 (27.5)	
20+	45 (6.6)	30 (66.7)	7 (15.6)	8 (17.8)	
Mean ± SD current BSA affected, %	15.2 ± 13.5	15.3 ± 13.9	15.1 ± 13.0	14.8 ± 12.6	0.9872
Current BSA affected group, n (%)					
0 – <5%	148 (21.8)	106 (71.6)	16 (10.8)	26 (17.6)	0.9939
5 – <10%	125 (18.4)	74 (59.2)	17 (13.6)	34 (27.2)	
10 – <15%	128 (18.9)	93 (72.7)	10 (7.8)	25 (19.5)	
15 – <20%	95 (14.0)	73 (76.8)	11 (11.6)	11 (11.6)	
20 – <25%	65 (9.6)	43 (66.2)	9 (13.8)	13 (20.0)	
25 – <30%	45 (6.6)	25 (55.6)	4 (8.9)	16 (35.6)	
30+%	72 (10.6)	51 (70.8)	9 (12.5)	12 (16.7)	
Number of other atopic conditions					
Mean ± SD	1.1 ± 1.2	1.0 ± 1.1	1.3 ± 1.2	1.2 ± 1.4	0.4360
Missing	63	38	4	21	
Presence of inflammatory atopic conditions, n (%)	346 (51.0)	244 (70.5)	42 (12.1)	60 (17.3)	0.1494
Presence of comorbidities, n (%)	553 (81.6)	377 (68.2)	63 (11.4)	113 (20.4)	0.8869
Presence of depression, n (%)	56 (8.3)	34 (60.7)	7 (12.5)	15 (26.8)	0.3773
Presence of anxiety, n (%)	99 (14.6)	63 (63.6)	13 (13.1)	23 (23.2)	0.5166
Hospitalised due to AD at any time, n (%)	74 (10.9)	43 (58.1)	10 (13.5)	21 (28.4)	0.1071

Variable^a	Overall (N = 678)	Matched (n = 465)	Patient assessed higher (n = 76)	Physician assessed higher (n = 137)	p value
Current treatment, n (%)					
Any systemic agent or phototherapy	320 (47.2)	211 (65.9)	40 (12.5)	69 (21.6)	0.3551
Non-systemics	358 (52.8)	254 (70.9)	36 (10.1)	68 (19.0)	
Currently on systemic immunosuppressant, n (%)	174 (25.7)	118 (67.8)	19 (10.9)	37 (21.3)	0.9197
Physician satisfaction with current control of patient's AD, n (%)					
Not satisfied	188 (27.7)	116 (61.7)	25 (13.3)	47 (25.0)	0.0562
Satisfied	490 (72.3)	349 (71.2)	51 (10.4)	90 (18.4)	

^aData available for all patients for all variables unless indicated as missing
BSA, body surface area; EASI, Eczema Area and Severity Index

Electronic Supplementary Material Table 2. Physician-Reported Data: Quality of Life

Variable ^a	Overall (N = 678)	Matched (n = 465)	Patient assessed higher (n = 76)	Physician assessed higher (n = 137)	p value
Impairment in ability to conduct normal daily activities / errands / tasks, n (%)					
No impairment	198 (29.4)	145 (73.2)	21 (10.6)	32 (16.2)	0.2351
Impairment	475 (70.6)	318 (66.9)	55 (11.6)	102 (21.5)	
Missing	5	2	0	3	
Itching interference,^b n (%)					
None at all [0-3]	363 (54.3)	248 (68.3)	40 (11.0)	75 (20.7)	0.9510
Interference [4-6]	305 (45.7)	211 (69.2)	34 (11.1)	60 (19.7)	
Missing	10	6	2	2	
Sleep disturbance interference,^b n (%)					
None at all [0-3]	531 (80.6)	377 (71.0)	51 (9.6)	103 (19.4)	0.0310
Interference [4-6]	128 (19.4)	77 (60.2)	21 (16.4)	30 (23.4)	
Missing	19	11	4	4	
Patients condition is a major problem in everyday life,^b n (%)					
Disagree [0-3]	463 (68.3)	313 (67.6)	54 (11.7)	96 (20.7)	0.7141
Agree [4-6]	215 (31.7)	152 (70.7)	22 (10.2)	41 (19.1)	
Patient is very knowledgeable about their condition,^b n (%)					
Disagree [0-3]	295 (43.5)	202 (68.5)	32 (10.8)	61 (20.7)	0.9421
Agree [4-6]	383 (56.5)	263 (68.7)	44 (11.5)	76 (19.8)	
Patient has learned to manage their condition over a long period,^b n (%)					
Disagree [0-3]	230 (33.9)	151 (65.7)	23 (10.0)	56 (24.3)	0.1467
Agree [4-6]	448 (66.1)	314 (70.1)	53 (11.8)	81 (18.1)	
Patient is not actively involved in the treatment decisions for their condition,^b n (%)					
Disagree [0-3]	595 (87.8)	409 (68.7)	69 (11.6)	117 (19.7)	0.5032
Agree [4-6]	83 (12.2)	56 (67.5)	7 (8.4)	20 (24.1)	

Variable^a	Overall (N = 678)	Matched (n = 465)	Patient assessed higher (n = 76)	Physician assessed higher (n = 137)	p value
Patient is always keen to try the next new treatment for their condition,^b n (%)					
Disagree [0-3]	416 (61.4)	279 (67.1)	47 (11.3)	90 (21.6)	0.4836
Agree [4-6]	262 (38.6)	186 (71.0)	29 (11.1)	47 (17.9)	
Patient is very concerned about the possible side effects of treatment,^b n (%)					
Disagree [0-3]	434 (64.0)	303 (69.8)	48 (11.1)	83 (19.1)	0.6102
Agree [4-6]	244 (36.0)	162 (66.4)	28 (11.5)	54 (22.1)	
Patient has become despondent in achieving better outcomes due to poor performance of available therapies,^b n (%)					
Disagree [0-3]	612 (90.3)	422 (69.0)	63 (10.3)	127 (20.8)	0.0567
Agree [4-6]	66 (9.7)	43 (65.2)	13 (19.7)	10 (15.2)	

^aData available for all patients for all variables unless indicated as missing

^bRated on a scale of 0-6

Electronic Supplementary Material Table 3. Patient-Reported Data: Satisfaction with Current Treatment and Quality of Life

Variable ^a	Overall (N = 678)	Matched (n = 465)	Patient assessed higher (n = 76)	Physician assessed higher (n = 137)	p value
Patient-reported satisfaction with how current treatment helps ad,^b n (%)					
Not satisfied	143 (24.2)	91 (63.6)	24 (16.8)	28 (19.6)	0.0687
Satisfied	447 (75.8)	317 (70.9)	44 (9.8)	86 (19.2)	
Missing	88	57	8	23	
Itching experienced at baseline,^b n (%)					
No	314 (46.3)	204 (65.0)	35 (11.1)	75 (23.9)	0.0807
Yes	364 (53.7)	261 (71.7)	41 (11.3)	62 (17.0)	
Pain / soreness due to AD experienced at baseline,^b n (%)					
No	498 (73.5)	332 (66.7)	56 (11.2)	110 (22.1)	0.1168
Yes	180 (26.5)	133 (73.9)	20 (11.1)	27 (15.0)	
Sleep disruption / insomnia due to AD experienced at baseline,^b n (%)					
No	599 (88.3)	415 (69.3)	62 (10.4)	122 (20.4)	0.1485
Yes	79 (11.7)	50 (63.3)	14 (17.7)	15 (19.0)	
DLQI					
Mean ± SD	7.05 ± 6.11	7.02 ± 6.02	9.74 ± 6.49	5.65 ± 5.75	<0.0001
95% CI	6.57, 7.52	6.45, 7.59	8.21, 11.26	4.65, 6.64	
Missing	43	32	4	7	
EQ-5D					
Mean ± SD	0.88 ± 0.14	0.89 ± 0.13	0.81 ± 0.16	0.89 ± 0.14	0.0003
95% CI	0.87, 0.89	0.87, 0.90	0.78, 0.85	0.86, 0.91	
Missing	21	16	2	3	
WPAI: percent overall work impairment due to problem					
Mean ± SD	20.9 ± 21.53	20.18 ± 20.05	29.25 ± 25.33	19.21 ± 24.18	0.0319
95% CI	18.83, 22.98	17.91, 22.46	21.26, 37.25	13.65, 24.77	
Missing	262	165	35	62	

^aData available for all patients for all variables unless indicated as missing

^bData from patient self-completion form

CI, confidence interval; DLQI, dermatology life quality index; WPAI, work productivity and activity impairment